

1 **What We Learned from COVID-19: From endotheliitis to treatment**

2 **Adem Dirican<sup>1</sup>, Selin Ildir<sup>2</sup>, Tugce Uzar<sup>2</sup>, Irem Karaman<sup>2</sup>, Sevket Ozkaya<sup>3</sup>**

3

4 <sup>1</sup>MD, Pulmonologist, VM Samsun Medicalpark Hospital, Department of Pulmonary Medicine,  
5 Samsun, Turkey.

6 <sup>2</sup>Medical Student/Intern, Bahcesehir University School of Medicine, Istanbul, Turkey.

7 <sup>3</sup>MD, Professor, Bahcesehir University Faculty of Medicine, Department of Pulmonary Medicine,  
8 Istanbul, Turkey

9

10

11

12 **Corresponding Author**

13 Sevket Ozkaya, MD, Pulmonologist, Professor, Bahcesehir University, Faculty of Medicine,  
14 Department of Pulmonary Medicine, Istanbul, Turkey.

15 E-mail: [ozkayasevket@yahoo.com](mailto:ozkayasevket@yahoo.com), mobile phone: +90 532 474 13 09

16

17 **Word count:** 5030

18 **Number of figures:** 1

19 **Number of tables:** 1

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38 **Abstract**

39 **Objective:** COVID-19 may yield a variety of clinical pictures, differing from pneumonitis to Acute  
40 Respiratory Distress Syndrome (ARDS) along with vascular damage in the lung tissue, named as  
41 *endotheliitis*. To date, no specific treatment strategy was approved by any authority for the prevention  
42 or treatment of COVID-19 in terms of endotheliitis-related comorbidities. Here, we present our  
43 experience of COVID-19 by evaluating 11,190 COVID-19 patients with the manifestations of  
44 endotheliitis in skin, lung, and brain tissues according to the different phases of COVID-19.

45  
46 **Methods:** After a retrospective examination, patients were divided into three groups according to their  
47 repercussions of vascular distress, which were represented by radiological, histopathological, and  
48 clinical findings. (Group A: no or mild pulmonary involvement, Group B: moderate pulmonary  
49 involvement with clinical risk of deterioration, Group C: severe pulmonary involvement and  
50 respiratory failure). We presented the characteristics and disease course of seven representative and  
51 complicated cases which represents the different phases of the disease, and discussed the treatment  
52 strategies in each group. The current pathophysiological mechanisms responsible from SARS-CoV-2  
53 infection, COVID-19 related respiratory failure and current treatment strategies were reviewed and  
54 discussed in detail.

55  
56 **Results:** Among 11.190 patients, 9294 patients met the criteria for Group A, and 1376 patients were  
57 presented to our clinics with Group B characteristics. Among these patients, 1896 individuals(Group B  
58 and Group C) were hospitalized. While 1220 inpatients were hospitalized within the first 10 days after  
59 the diagnosis, 676 of them were worsened and hospitalized 10 days after their diagnosis. Among  
60 hospitalized patients, 520 of them did not respond to group A and B treatments and developed  
61 hypoxemic respiratory failure (Group C) and 146 individuals needed ventilator support and were  
62 followed in the intensive care unit, and 43 (2.2%) patients died.

63  
64 **Conclusion:** Distinctive manifestations in each COVID-19 patient, including non-respiratory  
65 conditions in the acute phase and the emerging risk of long-lasting complications, suggest that  
66 COVID-19 has an *endotheliitis*-centred thrombo-inflammatory pathophysiology. Endotheliitis can  
67 also explain the mechanism behind the respiratory failure in COVID-19, and the difference of  
68 COVID-19 related ARDS from ARDS seen in other critical conditions. In addition, use of early  
69 corticosteroid in patients with early symptoms and early tocilizumab in ICU helps to reduce mortality  
70 and progression of the disease. Endotheliitis-based pathophysiological mechanisms are known to be  
71 momentarily changing and difficult to manage due to their risk of sudden aggravation. Hence, daily  
72 evaluation of clinical, laboratory and radiological findings of patients and deciding appropriate  
73 pathophysiological treatment would help to reduce the mortality rate of COVID-19.

74 **Keywords:** COVID-19, Acute Respiratory Distress Syndrome, Endotheliitis, Cytokine Storm, Plasma

75

## 76 **Introduction**

77 Novel coronavirus disease 2019 (COVID-19) has resulted in a dramatic pandemic crisis by causing  
78 mainly a respiratory disease that can rapidly progress to pneumonia and, in severe cases, to acute  
79 respiratory distress syndrome (ARDS) (1). Globally, as of July 15<sup>th</sup> of 2021, there have been  
80 187,519,798 confirmed cases of COVID-19, including 4,049,372 deaths, reported to World Health  
81 Organization (WHO)(2). The heterogeneity of the disease serves a spectrum from asymptomatic cases  
82 to respiratory failure. With the experiences from 11.190 COVID-19 patients since March 2020, we  
83 observed that distinctive clinical, radiological and histopathological manifestations of each COVID-19  
84 patient, including non-respiratory conditions in the acute phase and the emerging risk of long-lasting  
85 complications, suggests an *endotheliitis*-centred thrombo-inflammatory pathophysiology for COVID-  
86 19 (3). Therefore, understanding the pathophysiology of SARS-CoV-2 infection, and more  
87 significantly the host response against it, is a fundamental tool to develop a personalized treatment for  
88 the patient's need and momentary response. Accordingly, we adopted our treatment strategies  
89 depending on both the respiratory and vascular distresses observed in patients. In this paper, we aimed  
90 to present the clinical, radiological, and histopathologic manifestations of COVID-19 related  
91 endotheliitis, as well as present our treatment categories which were focused on preventing  
92 endotheliitis-related consequences in different phases of the disease.

93

## 94 **Methods**

### 95 *Patient Analysis and Classification*

96 All COVID-19 patients that were diagnosed and treated in Samsun VM Medicalpark Hospital, Turkey,  
97 between March 2020 and April 2021 were retrospectively evaluated. Patients who were suspected to  
98 be infected by SARS-CoV-2 were confirmed with clinic, laboratory (positive reverse-transcriptase-  
99 polymerase-chain-reaction assay of nasopharyngeal swabs or serological IgM/IgG rapid antibody test  
100 against SARS-CoV-2) and radiologic (consistent HRCT findings) results and included in the study.  
101 Demographic characteristics, presenting symptoms of the patients at the time of admission,  
102 radiological images, hospitalization status and the presence of need for respiratory support were  
103 retrieved from patient records at the time of admission. Confidentiality of the study participants'  
104 information was maintained throughout the study. The study was performed in accordance with the  
105 Helsinki Declaration and approval for this study procedure was obtained from the Istinye University  
106 Institutional Review Boards/ethical committees with respect to its scientific content.

107

### 108 *Three Main Groups for Different Phases SARS-CoV-2 Infection*

109 This heterogeneous population of patients were divided into three groups (A,B,C) according to their  
110 repercussions of vascular distress, which were represented by radiological, histopathological, and  
111 clinical findings. Division into three groups were made according to a combined criteria that was

112 adopted from WHO severity classification and the extent of endotheliitis, which were represented by  
113 the clinical symptoms, baseline oxygenations status, radiologic findings (chest x-ray/CT findings), and  
114 hemodynamic differences (4). Accordingly, three escalating phases of COVID-19 disease progression  
115 with associated signs, symptoms, and potential phase-specific treatments were described as early  
116 infection phase(Group A), progressive phase(Group B), and severe and dissipative phase(Group C).

117

118 The treatment modalities for each group were adopted from current local guidelines, as well as  
119 interventions that were later standardized according to clinical observation of momentary changes by  
120 two different pulmonologists (5-7).

121

122 **Group A.** Group A included patients who had any of the various signs and symptoms of COVID-19  
123 (e.g., fever, cough, sore throat, headache, muscle pain, diarrhea, loss of taste and smell) but did not  
124 have shortness of breath. Group A patients either presented no imaging findings of pneumonia, or they  
125 presented with the typical radiological representation of minimal patchy, subpleural, peripheral,  
126 perivascular ground-glass opacities (GGO) (Fig. 1-I and 1-II). The placement of GGOs in the early  
127 presentation of the disease is compatible with the distribution of microvascular capillaries of lung.

128

129 If the pulmonary involvement was absent or mild-to-moderate and the patient was suitable for  
130 ambulatory treatment, Favipiravir tablet (1600 mg BID for the first day, followed by 600 mg BID for  
131 four days, making five days in total), Dexamethasone (0.1-0.2 mg/kg per day), Azithromycin tablet,  
132 low-molecular-weight-heparin(LMWH) and acetylsalicylic acid(ASA) therapies were applied for one  
133 week.

134

135 **Group B.** Patients who showed evidence of lower respiratory disease during clinical assessment  
136 (respiratory symptoms) or imaging(findings of pneumonia) but an oxygen saturation(SpO<sub>2</sub>)  $\geq$ 94% on  
137 room air at sea level, were hospitalized for close follow-up. Patients with comorbidities or special  
138 conditions (i.e. age>65, diabetes, cancer, obesity, cardiovascular disease, chronic lung disease, sickle  
139 cell disease, chronic kidney disease, being pregnant, cigarette smoking, transplant or  
140 immunosuppression recipient) were also hospitalized due to their high risk of severity<sup>4</sup>. Patients who  
141 had moderate pulmonary involvement or unresponsive to the Group A treatment in terms of the  
142 clinical symptoms, with no evident respiratory failure, but had been indicated for hospitalization were  
143 classified as Group B. Group B corresponds to the progressive phase of the disease, which is  
144 characterized by multifocal, bilaterally diffused GGOs with poorly circumscribed consolidations  
145 scattered in peripheral zones of lungs, along with vascular and intra-lobular septal thickenings called  
146 “crazy paving pattern” (Fig.1-IIIb) (7).

147

148 For this group, Favipiravir tablet (1600 mg BID for the first day, followed by 600 mg BID for four  
149 days, making five days in total), Dexamethasone (0.1-0.2 mg/kg per day) or methylprednisolone (1-2  
150 mg/kg per day), Azithromycin tablet or fluoroquinolone, LMWH, ASA and Famotidine tablet  
151 therapies were prescribed. Although the treatment takes one week, we observed that this phase has the  
152 peak stage in 10-13 days and may include potential secondary complications. Thus, patients require a  
153 close follow-up by serial chest X-rays to establish a baseline to assess the improvement of aeration.

154

155 **Group C.** Patients with moderate to severe pulmonary involvement(lung infiltrates >50%),  
156 accompanied by respiratory failure(SpO<sub>2</sub> <94% on room air at sea level and , a ratio of arterial partial  
157 pressure of oxygen to fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) <300 mm Hg, respiratory frequency  
158 >30 breaths/min), or to the patients who were recalcitrant to standard therapy and had deteriorating  
159 clinical status with laboratory (particularly increasing ferritin levels) and radiological findings were  
160 classified as Group C. In addition, patients who showed rapid progression(>50%) on CT imaging and  
161 who presented with respiratory failure or shock within 24-48 hours also included in this group. This  
162 group represents the progressive, peak, dissipative and severe phases of the disease. The radiological  
163 findings of Group C were microscopic lacerations and infiltrations in perialveolar vessels which were  
164 radiologically appeared as developing pulmonary GGOs, consolidation and diffuse alveolar damage  
165 (DAD), which may be accompanied by pneumothorax, pneumomediastinum or intracranial  
166 hemorrhage at this stage(Fig. 1-IV-V-VI-VII).

167

168 For this severe group of patients, Favipiravir tablet (1600 mg BID for the first day, followed by 600  
169 mg BID for 4 days, continued for 5 or 10 days in total), methylprednisolone (250-1000 mg/day for at  
170 least three days), convalescent plasma(once in a day during the first and second days of radiological  
171 deterioration, applied for maximum three days), tocilizumab(400 mg QD/daily, applied two times),  
172 supported by Piperacilin/Tazobactam, LMWH and famotidine therapies were administered. The  
173 effectiveness of this group of treatment was measured by overall mortality ratio.

174

## 175 **Results**

176 A total of 11.190 patients were evaluated. The mean age was 59.2 ±17.3 years and male to female  
177 ratio was 5507/5683. Among 11.190 patients, 9294 (83,05%) patients met the criteria for Group A,  
178 and 1376 (12.29) patients were presented to our clinics with Group B characteristics. Among these  
179 patients, 1896 (16.9%) individuals(Group B and Group C) were hospitalized. While 1220 inpatients  
180 were hospitalized within the first 10 days after the diagnosis, 676 of them were worsened and  
181 hospitalized 10 days after their diagnosis. Among hospitalized patients, 520 (4.64%) of them did not  
182 respond to group A and B treatments and developed hypoxemic respiratory failure (Group C). Among  
183 patients who developed hypoxemic respiratory failure, 146 (7.7%) individuals needed ventilator  
184 support (non-invasive/invasive mechanical ventilation) and were followed in the intensive care unit,

185 and 43 (2.2%) patients died. As a complication, among 11.190 patients, 30 patients developed either  
186 spontaneous pneumothorax, pneumomediastinum or subcutaneous emphysema, and 4 patients died  
187 with a 13.3% mortality rate.

188

189 Radiologic images and histopathologic samples of representative groups are presented in **Figure 1**  
190 which consists of 7 representative and complicated cases with variable stages of COVID-19, together  
191 with additional examples of findings of early and severe endotheliitis in brain, pulmonary and skin  
192 tissues. Representative cases for early phase:Group A (Fig.1-I,II), progressive phase:Group B(Fig.1-  
193 III), severe and dissipative phase:Group C(Fig.1-IV,V,VI,VII) were presented and cases were  
194 presented in Figure 1.

195

196 **Case 1(Figure 1-I)** was a female patient who was in her 50's and admitted to the hospital with  
197 complaints of cough and fever. She was diagnosed with COVID-19 due to PCR positivity. HRCT  
198 images showed patchy, subpleural and peripheral perivascular ground-glass opacities, corresponding  
199 the early phase of pneumonitis. She received Group A treatment. GGOs in transaxial images were  
200 located in the subpleural area, where the microvascular *endoteheliitis* and endothelial destructions  
201 mostly likely occur, due to the interaction with toxic plasma in the capillaries of pulmonary interstitial  
202 space. She was completely recovered at 14<sup>th</sup> days at control appointment, after 5 days of treatment  
203 with favipiravir.

204

205 **Case 2(Figure 1-II)** was a male patient who was 47-52 years old and admitted to the hospital with  
206 complaints of fever and chest pain. His COVID-19 PCR test was positive. In addition to the  
207 characteristics of an early phase COVID-19 pneumonitis (end-capillary microangiopathy, explained in  
208 Fig.1-I) his HRCT images showed perivascular consolidation. It appeared as the continuation of crazy-  
209 paving pattern, which was demonstrated by the thickening in inter-lobular and intra-lobular septa.  
210 Lung involvement was limited and monofocal. Hence, the patient received Group A treatment. He was  
211 completely recovered at 14<sup>th</sup> days at control appointment, after 5 days of treatment with favipiravir.

212

213 **Case 3(Figure 1-III)** was a male patient whose age ranged between 63-68 and admitted to the hospital  
214 with complaints of fever and cough. His PCR test resulted positive for SARS-CoV-2. Transaxial  
215 HRCT image in the first day of positivity shows bilateral and patchy nodular GGOs as expected in  
216 early phase (**IIIa**). He received group B treatment and hospitalized for close follow-up. At the 5th day  
217 of positivity, affected pulmonary areas were advanced into scattered consolidations (**IIIb**). This  
218 appearance was noted as the progressive phase of pneumonitis and was considered as representation of  
219 clinical deterioration clinically (i.e. dyspnea, respiratory failure). On the 15<sup>th</sup> day of positivity,  
220 fibroreticular consolidations were conspicuous (**IIIc**). The dissipative phase was the healing process,  
221 characterized by the resolution in lung parenchyma and residual GGO, observed after 35 days of

222 positivity (**III**d). Parenchymal bands, originated from previous fibroreticular proliferation, were also  
223 visible (**III**d).

224

225 If the patients have a tendency of severe phase and/or unresponsiveness to Group B therapy, **Group C**  
226 treatment was used. Representative cases of this group are shown in sections **IV-V-VI-VII**. This group  
227 of patients also underwent early and progressive phases of COVID-19 but they showed further  
228 deterioration of lung involvement and endothelial damage, therefore, they received the last group of  
229 treatment.

230

231 **Case 4(Figure 1-IV)** was a male patient whose age ranged between 53-58 and admitted to the hospital  
232 with complaints of fever. His PCR test was positive results positive for SARS-CoV-2. Coronal,  
233 sagittal and axial planes of HRCT images initially showed small GGO with a local subpleural sparing,  
234 particularly around the microvascular area on the first day of positivity (**IV**a). In the 5<sup>th</sup> day of  
235 treatment, increased GGOs were visible in the progressive phase (**IV**b). After 18 days of positivity,  
236 pneumomediastinum, Diffuse Alveolar Damage (DAD) and ARDS were seen in the severe phase  
237 (**IV**c). Lastly, the dissipative phase was seen, after 30 days of positivity, with residual fibrotic  
238 parenchyma (**IV**d).

239

240 **Case 5(Figure 1-V)** was a female patient whose aged ranged between 49-53 and admitted to the  
241 hospital with complaints of fever and cough. Her COVID-19 PCR test was positive. Her first HRCT,  
242 on the 2<sup>nd</sup> day of positivity, showed COVID-19-related bilateral and multifocal nodular GGOs (**V**a).  
243 After 10 days of positivity, DAD developed along with ARDS and pneumomediastinum characterized  
244 with the severe phase (**V**b). She recovered and discharged after 30 days of positivity with the  
245 dissipative phase (**V**c). The regression in pulmonary lesions was visible on the HRCT image two  
246 months after diagnosis (**V**d).

247

248 **Case 6(Figure 1-VI)** was a male patient whose age ranged between 50-55 and admitted to the  
249 hospital with complaints of fever and cough. His COVID-19 PCR test was positive. His HRCT  
250 showed moderate pneumonia in the early phase (**VI**a). After 12 days of positivity, the severe phase  
251 develops with DAD and ARDS (**VI**b). In the 25<sup>th</sup> day of positivity, recovery was observed in the  
252 dissipative phase (**VI**c). The extent of improvement in pulmonary lesions can be noticed in **VI**d,  
253 which was 40 days after the diagnosis.

254

255 **Case 7(Figure 1-VII)** was a male patient whose age ranged between 48-53 and admitted to the  
256 hospital with complaint of dyspnea. His COVID-19 PCR test was positive. His first HRCT showed  
257 ARDS pattern with dense consolidations (**VII**a). Pneumothorax developed after two weeks from

258 diagnosis (**VIIIb**). In addition to the respiratory failure, hemorrhagic intracranial areas were seen in  
259 the T2-weighted MRI. (**VIIIc**). He was lost at the 20<sup>th</sup> day of positivity.

260

261 The demonstration of endotheliitis in the biopsy section of lung parenchyma (Fig.1-VIII), radiological  
262 images of brain(Fig.1-IX) and lung(Fig.1-X,XI), and skin manifestation(Fig.1-XII) of endotheliitis are  
263 also presented in Figure 1.

264

## 265 **Discussion**

### 266 **Are Laboratory Findings' Reliable in Determining the COVID-19 Course & Prognosis?**

267 Our classification of patient population and treatment groups was primarily based on the clinical and  
268 radiological findings, rather than the laboratory findings. During a year of the pandemic, in our clinics,  
269 we observed that even though the laboratory findings may show the degree of pathophysiology during  
270 the disease course, it may mislead the clinician when it comes to clinical practice. While C-reactive  
271 protein, ferritin, lactate dehydrogenase, erythrocyte sedimentation rate, IL-6 elevation and TNF-alpha  
272 represent inflammatory changes; D-dimer, prolonged PTT and troponin elevation show the  
273 predisposition to thrombosis and myocardial damage (8,9). Cheng et al. points out that severely  
274 affected patients, along with the ones who could not survive the disease, are subject to significantly  
275 higher ferritin levels in comparison to the non-severe and survivor groups of patients (10). However,  
276 COVID-19 is an acute syndrome of different age and comorbidity groups. When the clinician fails to  
277 detect the pre-infectious baseline values of the patient, overtreatment may worsen the situation. In our  
278 study group, a patient with 250 mg/L ferritin received Group C treatment, while another with 2550  
279 mg/L received Group A due to the difference in their previous normal values (ferritin increased 10 and  
280 <1 times, respectively). The change in the concentrations of inflammatory markers seem to be  
281 significantly different in COVID-19 than in typical non-COVID-19-related ARDS, suggesting that  
282 COVID-19 features its own unique, poorly understood, yet detrimental, inflammatory profile (11).  
283 Therefore, we advise the categorization and treatment strategies to be selected by monitoring  
284 radiological findings and the severity of clinical features (such as dyspnea and oxygen saturation).

285

### 286 **Farsighted Evaluation: What are the Causes in Pathogenic Scene After Infection with SARS- 287 CoV-2?**

#### 288 *Cytokine Storm and Emergence of Toxic Plasma*

289 Pathophysiology of COVID-19 is closely related to cytokine storm, which arises from the consecutive  
290 and intricate activation of numerous inflammatory cells that cause excessive and/or unregulated,  
291 proinflammatory cytokine release (13). Cytokines force blood plasma to undergo a chemical  
292 alteration, revealing toxic and irritant characteristics. Cytokine storm comprises the systemic  
293 activation of unstimulated tissue cells, epithelial and endothelial cells in addition to hyperactivation of  
294 hematopoietic cells, including B lymphocytes, natural killer (NK) cells, macrophages, dendritic cells,

295 neutrophils and monocytes which provoke the excessive release of proinflammatory cytokines (14).  
296 This toxic setting not only causes inflammation but also a damage in various systemic tissues via the  
297 signals of pro-apoptosis (15). Main clinical manifestations of cytokine storm appear as fever,  
298 progressive dyspnea, tachypnea and elevated inflammatory markers such as IL-6, CRP and ferritin as  
299 it is observed in COVID-19 patients (14,15). The uncontrolled production of pro-inflammatory factors  
300 (IL-6, IL-8, IL-1 $\beta$ , and GM-CSF), and chemokines (CCL2, CCL3, CCL-5) together with reactive  
301 oxygen species (ROS) cause ARDS which leads to pulmonary fibrosis and death. Abnormal nitric  
302 oxide metabolism, upregulation of ROS and proteases, downregulation of endothelium-associated  
303 antioxidant defense mechanisms, and induction of tissue factor altogether provide a basis for vascular  
304 pathology in COVID-19 (3).

305  
306 Additionally, the systemic inflammatory response against SARS-CoV-2 infection is supported by the  
307 circulating mediators found in different organ systems, which are demonstrated in postmortem  
308 histopathological analysis to indicate the organ-dependent cytokines (16,17). Fig.1-VIII represents the  
309 areas of lung parenchyma with the mixt-type inflammatory-cell infiltration and exudative capillaritis  
310 with thickened microvascular walls, in addition to the interstitial and intra-alveolar proliferation of  
311 fibroblasts.

312

### 313 ***Vascular Effects: Endotheliitis, Thromboinflammation and Systemic Microangiopathy***

314 Endotheliitis, hypercoagulability and thrombotic microangiopathy are namely the vascular hallmarks  
315 of COVID-19 (18,19). These vascular complications should be evaluated separately from ARDS. As  
316 a matter of fact, the histopathologic changes observed in several tissue samples might be primarily the  
317 result of C3-mediated pathways in thromboinflammation(18). Beigee et al. stated that vascular  
318 widespread platelet-fibrin microthrombi was the main pathologic finding in the lung samples of  
319 critical COVID-19 patients with severe hypoxemia and minor radiological abnormalities on imaging  
320 (16). They also indicated that clinically not all patients with ARDS present DAD. However, the  
321 presence of DAD with ARDS contributes worsening of clinical outcomes when compared with those  
322 without DAD. Early and late endotheliitis lesions on pulmonary HRCT are seen in Fig.1-X-XI.

323

324 Varga et. al were first to demonstrate that irritant plasma, together with the SARS-CoV-2 infection,  
325 cause ‘*endotheliitis*’ in microvascular capillary endothelium, which is the primary pathology seen  
326 under non-immune, corrosive and irritant conditions (20). Similarly, Zhang et al. demonstrated that  
327 COVID-19 infection resembles more of the pathophysiology and phenotype of complement-mediated  
328 thrombotic microangiopathies(TMA); rather than sepsis-induced coagulopathy or disseminated  
329 intravascular coagulation (21). A common denominator of complement-mediated effects in TMAs is  
330 angiocentric inflammation causing endothelial dysfunction; mononuclear and neutrophilic  
331 inflammation of microvessels and as a result, microvascular thrombosis, which brings poor prognosis,

332 multiple organ dysfunction syndrome and ARDS(22). Microangiopathies in COVID-19 patients are  
333 characterized by anemia, increased lactate dehydrogenase, thrombocytopenia and organ damage (ex.  
334 skin lesions, neurological, renal and cardiac dysfunction) (22,23). In our cohort of patients, skin  
335 lesions were seen as COVID-19-associated papulovesicular exanthema scattered in trunk and mild  
336 pruritus (Fig.1-XII). Trellu et al. indicated that histopathological findings of papulovesicular eruption  
337 reveal the signs of *endotheliitis* and microthrombosis in the dermal vessels (24). Unfortunately,  
338 patients may die, not from respiratory failure, but due to the vascular coagulopathies (i.e.hemorrhage)  
339 in brain, kidneys and heart (Fig.1-IX).

340

#### 341 **Fundamentals Behind COVID-19 Related Respiratory Failure**

342 Endothelial dysfunction plays a key role in understanding the multisystemic attack of SARS-CoV-2  
343 infection. Microvascular capillary *endotheliitis* is the primary mechanism that cause clinical  
344 deterioration, particularly in those patients with advanced pulmonary involvement (25). The critical  
345 point in this manner is to differentiate non-immune *endotheliitis* from immune complex endotheliitis  
346 in lungs, and to consider it as the main pathology of COVID-19 since it is not directly mediated by the  
347 active antigen-antibody complexes or the virulence of SARS-CoV-2 itself (26,27).

348

349 Initially, the irritant action of plasma leads to the thickening of the vessel wall and deceleration in  
350 blood flow, which is responsible for the microthrombosis in capillary beds in lungs, which may lead to  
351 respiratory failure. Fox et al. demonstrated the microvascular thrombosis and hemorrhage in lungs, as  
352 a remarkable contributor of death, in the autopsies of COVID-19 non-survivors (28). They also proved  
353 that the cardiovascular damage is “non-immune” by demonstrating cardiac cell necrosis without  
354 lymphocytic myocarditis in deceased patients.

355

356 The concept of virus-induced pulmonary vasculitis is consistent with a substantial  
357 ventilation/perfusion mismatch in COVID-19 based on a right-to-left pulmonary shunt due to a vicious  
358 cycle beginning with an increase in respiratory effort and oxygen consumption in inflamed and  
359 hyperperfused lungs, failure of hypoxic vasoconstriction, and resulting fatal outcome (3). Therefore,  
360 the failure of simple ventilatory support in COVID-19 is commonly observed in patients who are  
361 unable to satisfy the oxygen demand due to reduced lung capacity (such as older patients and patients  
362 with obesity) and cardiovascular comorbidities.

363

364 In the clinical presentation, aggravation of dyspnea and hypoxemia symptoms were attributed to  
365 dysfunctional crosstalk between leukocytes and endothelial cells that manifest as vascular  
366 immunopathology predominantly confined to the lungs. Eventually, since microvascular walls are  
367 prone to damage, the destruction most conveniently occurs as *endotheliitis* at the site of pulmonary  
368 interstitial capillaries; with the help of lung elasticity and thin vascular walls, conveys into the

369 perivascular space(29). Remarkably, due to SARS-CoV-2's endotheliophilic nature, endothelial and  
370 epithelial infections appear to be the predominating factors during the course of the disease (3). On the  
371 other hand, alveolar-centered infection and the disruption of alveolar epithelial–endothelial barriers  
372 contribute to the development of DAD and *pneumonitis*, which manifest as GGOs in alveolar spaces  
373 (30,31) (Fig.1-III and VIII). The aforementioned endothelial damage may spread to different systems  
374 and become lethal (Fig.1-VII).

375

376 Ekanem et al. stated that higher inflammatory markers (ferritin, CRP and fibrinogen), increased  
377 fibrosis in HRCT images, and absence of receiving an interleukin-6 inhibitor or convalescent plasma  
378 are associated with higher probability of severity and mortality via the spontaneous pneumothorax  
379 (SPT) (32). They also suggested that there must be factors uniquely associated with COVID-19 that  
380 contribute to the incidence of SPT, since half of the patients were not on a ventilator when the  
381 pneumothorax was diagnosed. In Group C (Fig.1-IV-V-VI-VII), we also observed that endothelial  
382 damage, along with thromboinflammation, brought increased incidence of pneumothorax secondary to  
383 DAD in patients with ARDS. Here, among 11.190 patients, 30 patients developed either SPT,  
384 pneumomediastinum or subcutaneous emphysema with a 13.3% mortality rate. The most important  
385 reason behind these complications was most likely DAD, which stems from the high transpulmonary  
386 pressure and alveolar wall vulnerability, with decreased compliance and increased frailty, resulting in  
387 an air leakage into the chest compartments(33). SPT that is observed in severe COVID-19 patients, is  
388 thought to be derived from reduced alveolar vessel caliber due to the virus-induced cytolysis,  
389 mononuclear immunological response to injury and the small vessel thrombosis at the site of  
390 perialveolar area, which should be differentiated from iatrogenic pneumothorax related to mechanical  
391 ventilation (34).

392

### 393 **Prevention of Aforementioned Microvascular Pathology and Mortality**

394 Planning an effective therapy for COVID-19 infection is a complex process. According to Mastellos et  
395 al. broader pathogenic involvement of C3-mediated pathways in thromboinflammation supports the  
396 utilization of complement inhibitors in COVID-19, which result in diminished hyper-inflammation  
397 and marked lung function improvement(35). Teuwen et al. suggested that normalization of vascular  
398 walls through metabolic interventions might be considered as an additional potential target for the  
399 therapy(36). Therefore, until a specific antiviral is discovered against SARS-CoV-2, convalescent  
400 plasma therapy and immunomodulators play a significant role to control the consequences of SARS-  
401 CoV-2 infection (i.e. cytokine storm), to reduce inflammatory cell infiltration in lungs and to prevent  
402 fatal course in severe patients by reducing the likelihood of the Systemic Inflammatory Response  
403 Syndrome (37).

404

405 The latest COVID-19 treatment guideline published by the Turkish Ministry of Health included the  
406 favipiravir, ASA, famotidine, LMWH, dexamethasone , tocilizumab, which were shown to be safe and  
407 in vitro effective against SARS-CoV-2 (5,6). Based on indirect evidence from different clinical trials,  
408 convalescent plasma therapy and pulse steroid therapy were also suggested for severe patients (38).  
409 The required interventions were made according to clinical severity of patients, vitals, time from  
410 symptom onset and radiological images.

411

412 **Convalescent plasma** therapy plays a critical role in neutralizing the plasma and diminishing its  
413 corrosiveness. Convalescent plasma not only demonstrates an antibody response but also denotes  
414 immunomodulatory, anti-cytokine and proinflammatory effects, which appear as key factors to  
415 minimize disease severity and mortality in COVID-19 cases(38). Gomez-Pastora et al. explain this  
416 correlation by the phenomena of pro-inflammatory and anti-inflammatory cytokine activation, as a  
417 result of macrophage associated hyperferritinemia(39). They stated that ferritin plays an active role as  
418 a pathogenic mediator in COVID-19 and the therapeutic use of plasma is beneficial to reduce ferritin  
419 and cytokine levels in the body. Our experience with convalescent plasma showed rapid and positive  
420 results against the symptoms of dyspnea, hypoxemia, fever and radiologically seen infiltrations, which  
421 was demonstrated **in Case 4-7**.

422

423 **Antiviral drugs** are being used to decrease the viral load. Correspondingly, Favipiravir was the drug of  
424 choice that is recommended by Turkish Republic of Health Ministry guidelines (5,6). However, it  
425 should be noted that antiviral therapy fails to prevent pulmonary involvement, which is the result of  
426 inflammatory process rather than the effect of SARS-CoV-2 infection itself (40).

427

428 **Systemic corticosteroid drugs** (dexamethasone and methylprednisolone) are the only effective  
429 therapeutic agents to repair non-immune capillary microvascular *endotheliitis*, hence, advised to be  
430 used even in the presence of minimal ground-glass opacities(41). In our clinical experience, to benefit  
431 the best of steroids, steroids should be utilized in the early phase, rather than the progressive phase  
432 (approximately the second week of infection). Minimally distributed GGOs may easily progress to  
433 severe ARDS, in the absence of steroid treatment (**Fig.1-VIIa-VIb**). In a multi-centered study  
434 conducted by RECOVERY Collaborative Group, mortality ratio in patients, who receive oxygen  
435 support and dexamethasone, found to be lower than the control group, especially if the patients are  
436 receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81)  
437 (42). Although the role of corticosteroids in COVID-19 has been well-recognized in the therapeutic  
438 algorithm, the right timing, dosage and duration of corticosteroid use is still unknown. Pinna et al.  
439 suggested that although the early use of corticosteroids might facilitate the viral replication in the  
440 upper airways, late administration fails to prevent the alveolar damage(43). It has been suggested that  
441 early initiation of low-dose methylprednisolone therapy (with up to 40mg/day for less than 10 days)

442 provides clinical, radiological improvement in patients with active disease state of COVID-19, by  
443 reducing the immune cascade and progression into cytokine without any adverse effect (44-46).

444

445 *Immunomodulatory therapies* help to diminish the cytokine response of the body. Tocilizumab  
446 therapy, a monoclonal IL-6 antagonist, reduced the likelihood of progression to the composite  
447 outcome of mechanical ventilation or death (47). Capra et al. have demonstrated that tocilizumab can  
448 be used as an immunomodulatory drug of choice in case of the severe COVID-19 to reduce mortality,  
449 diminish oxygen intake and treat lung opacities as well (48). Findings by Gupta et al. also supported  
450 the early use of (within first 2 days of ICU) tocilizumab to reduce the in-hospital mortality among  
451 critically ill patients with COVID-19 (49).

452

453 **LMWH and ASA** are well-known to prevent the formation of microvascular thrombosis and cure  
454 hypoxemia, thus can be used as supportive treatment against cardiovascular complications of COVID-  
455 19 (50). However, before the use of ASA, patient history should be questioned in terms of renal  
456 failure, gastrointestinal system disease, cardiovascular disease. Local current guidelines recommended  
457 the use of NSAIDs, especially in the first 5-10 days; and steroid treatment to be started in the early  
458 period in patients who worsen after theoretical viral clearance is completed in the first 5-10 days (5).

459

#### 460 **Limitation**

461 We acknowledge that there are confounding factors related to management of COVID-19 patients due  
462 to lack of a standardized guideline for treatment of each and every patient. However, while the in-  
463 hospital mortality was reported to be up to 25% in different prospective trials, we believe that our  
464 standardized treatment approach, which has a result of 2.2% in-hospital mortality, represent the  
465 success of the personalized management of each COVID-19 patient in a single center (50). As the  
466 COVID-19 pandemic continues, our current strategy represents a snapshot that would most probably  
467 change drastically over time.

468 As a limitation, the design of the current study does not allow for further analysis of the COVID-19  
469 patients in terms of the change in their laboratory, clinical and radiological parameters and  
470 investigation of the effects of different SARS-CoV-2 variants (such as Alpha, B.1.1.7, Beta B.1.351, or  
471 Delta B.1.617.2) in the clinical presentation of the patients. The observational methodology suggested  
472 may be a source of bias that could lead to wrong conclusions on the effectiveness of treatments and the  
473 clinical representation of the underlying pathophysiology. Provided treatment strategies are  
474 implemented to all patients regardless of their SARS-CoV-2 variant types. No corruptions from  
475 Turkey's Ministry of Health guidelines are enforced to the patients in terms of new experimental drugs  
476 and/or biological agents.

477 We would like to declare that, our study did not interfere any patient's right to receive treatment by  
478 addressing a control group in a pandemic situation. Here, we also did not aim to demonstrate the  
479 effectiveness of the therapy in the means of laboratory data, however we aimed to present the  
480 representations of the required interventions in the each group of patients, by preventing the  
481 progression of endotheliitis. Therefore, we used the current literature to support our clinical  
482 observation and own perspective. In this end of the study, our aim was to declare our own point of  
483 view by using our clinical experience, clinical representation of endotheliitis and the current literature.  
484 We would like to approach to the vascular distress phenomenon as a clinical parameter that can be  
485 used practically in the clinics, both by recognizing from radiological images and clinical findings of  
486 the patients

## 487 **Conclusion**

488 SARS-CoV-2 infection is a multisystemic disease which courses rapidly with respiratory failure and  
489 complications secondary to vascular alterations (i.e. microvascular thrombosis, *endotheliitis*, and  
490 cytokine induced plasma toxicity). Early detection of radiological deterioration before laboratory  
491 findings, via monitoring chest X-rays daily, and planning personalized treatments constitute a crucial  
492 and life-saving maneuver in the treatment of COVID-19. Our group suggests that an important key to  
493 success relies on how closely the clinicians follow patients from diagnosis to treatment, including the  
494 whole course of the disease from outpatient clinic to ICU, in order to differentiate instant clinical  
495 deviations from previous general status

496 Distinctive manifestations in each COVID-19 patient, including non-respiratory conditions in the  
497 acute phase and the emerging risk of long-lasting complications, suggest that COVID-19 has an  
498 *endotheliitis*-centred thrombo-inflammatory pathophysiology. Potential pathophysiological  
499 mechanisms contributing to endotheliitis includes cytokine storm and toxic plasma,  
500 thromboinflammation and systemic microangiopathy. Endotheliitis can also explain the mechanism  
501 behind the respiratory failure in COVID-19, and the difference of COVID-19 related ARDS from  
502 ARDS seen in other critical conditions. In our observations, utilization of early dexamethasone in  
503 Group A prevented the progression of the COVID-19 into more severe form. In addition, use of early  
504 steroid in Group A and early tocilizumab in group C helps to reduce mortality and progression of the  
505 disease. Endotheliitis-based pathophysiological mechanisms are known to be momentarily changing  
506 and difficult to manage due to their risk of sudden aggravation. Hence, daily evaluation of patients and  
507 deciding appropriate pathophysiological treatment for the momentary changes in clinical, laboratory  
508 and radiological findings would help to reduce the mortality rate of this novel virus. The collaboration  
509 of scientists and clinicians around the world is required in order to develop novel prognostic  
510 biomarkers and establish precise predictive thresholds for known biomarkers to foresee the severity

511 for COVID-19 pneumonitis that is characterized by vasculopathies and wide range of immune  
512 derangements.

513

#### 514 **Disclosure**

515 The authors have no conflicts of interest to declare.

516

#### 517 **Ethics Statement**

518 The patients signed written informed consents to be able to provide data in this study. The study was  
519 performed in accordance with the Helsinki Declaration and approval for this study procedure was  
520 obtained from the Istinye University Institutional Review Boards/ethical committees with respect to its  
521 scientific content.

522

#### 523 **Authors' Contribution**

524 AD and SO diagnosed, treated the patients and designed the analysis, SI, TU and IK collected the data,  
525 analysis tools and wrote the paper.

526

#### 527 **Data Availability**

528 The research article data used to support the findings of this study are available from the  
529 corresponding author upon request.

#### 530 **References**

531 1. Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? *Critical Care*.  
532 2020;24(1):1-5.

533 2. “Coronavirus Update (Live)-Worldmeter”(retrieved May 11,2021). [www.worldometers.info](http://www.worldometers.info)

534 3. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, et al.  
535 The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity.  
536 *The Lancet Respiratory Medicine*. 2021.

537 4. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019  
538 (COVID-19): A Perspective from China. *Radiology*. 2020;296(2):E15-E25.

539 5. Republic of Turkey Ministry of Health. COVID-19 Interim Guidance (T.C. Sağlık Bakanlığı  
540 COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi) 2020. Available from:  
541 [https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19\\_Rehberi.pdf?type=file](https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf?type=file).

- 542 6. Köktürk N, İtil BO, Altınışık G, Adıgüzel N, Akgün M, Akyıldız L, et al. COVID-19  
543 Pandemic and the Global Perspective of Turkish Thoracic Society. Turkish thoracic journal.  
544 2020;21(6):419-32.
- 545 7. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment  
546 Guidelines. 2021. National Institutes of Health. Accessed 2021 Mar 28.  
547 <https://www.covid19treatmentguidelines.nih.gov/>
- 548 8. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for  
549 monocytes and macrophages. Nature Reviews Immunology. 2020;20(6):355-62.
- 550 9. Grasselli G, Tonetti T, Protti A, Langer T, Girardis M, Bellani G, et al. Pathophysiology of  
551 COVID-19-associated acute respiratory distress syndrome: a multicentre prospective  
552 observational study. The lancet Respiratory medicine. 2020;8(12):1201-8.
- 553 10. Cheng L, Li H, Li L, Liu C, Yan S, Chen H, et al. Ferritin in the coronavirus disease 2019  
554 (COVID-19): A systematic review and meta-analysis. Journal of clinical laboratory  
555 analysis. 2020;34(10):e23618.
- 556 11. Sinha P, Calfee CS, Cherian S, Brealey D, Cutler S, King C, et al. Prevalence of phenotypes  
557 of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective  
558 observational study. The Lancet Respiratory Medicine. 2020;8(12):1209-18.
- 559 12. Ufuk F, Savaş R. Chest CT features of the novel coronavirus disease (COVID-19). Turkish  
560 journal of medical sciences. 2020;50(4):664-78.
- 561 13. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19:  
562 An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine &  
563 growth factor reviews. 2020;53:25-32.
- 564 14. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the Cytokine Storm in COVID-19.  
565 Journal of infection. 2020;80(6):607-13.
- 566 15. Becker RC. COVID-19-associated vasculitis and vasculopathy. Springer; 2020.
- 567 16. Beigee FS, Toutkaboni MP, Khalili N, Nadji SA, Dorudinia A, Rezaei M, et al. Diffuse  
568 alveolar damage and thrombotic microangiopathy are the main histopathological findings in  
569 lung tissue biopsy samples of COVID-19 patients. Pathology-Research and Practice.  
570 2020;216(10):153228.

- 571 17. Elsoukkary SS, Mostyka M, Dillard A, Berman DR, Ma LX, Chadburn A, et al. Autopsy  
572 findings in 32 patients with COVID-19: a single-institution experience. *Pathobiology*.  
573 2021;88(1):55-67.
- 574 18. Mosleh W, Chen K, Pfau SE, Vashist A. Endotheliitis and endothelial dysfunction in patients  
575 with COVID-19: its role in thrombosis and adverse outcomes. Multidisciplinary Digital  
576 Publishing Institute; 2020.
- 577 19. Calabretta E, Moraleda JM, Iacobelli M, Jara R, Vlodaysky I, O’Gorman P, et al.  
578 COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies.  
579 *British Journal of Haematology*. 2021;193(1):43.
- 580 20. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.  
581 Endothelial cell infection and endotheliitis in COVID-19. *The Lancet*. 2020;395(10234):1417-  
582 8.
- 583 21. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid  
584 antibodies in patients with Covid-19. *New England Journal of Medicine*. 2020;382(17):e38.
- 585 22. Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic  
586 microangiopathy and complement activation: potential role of complement system inhibition  
587 in COVID-19. *Journal of thrombosis and thrombolysis*. 2021;51(3):657-62.
- 588 23. Thakur V, Ratho RK, Kumar P, Bhatia SK, Bora I, Mohi GK, et al. Multi-organ involvement  
589 in COVID-19: beyond pulmonary manifestations. *Journal of clinical medicine*.  
590 2021;10(3):446.
- 591 24. Trellu LT, Kaya G, Alberto C, Calame A, McKee T, Calmy A. Clinicopathologic aspects of a  
592 papulovesicular eruption in a patient with COVID-19. *JAMA dermatology*. 2020;156(8):922-  
593 4.
- 594 25. Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepaspe P-R, Fobker M, et al. Microvascular  
595 dysfunction in COVID-19: the MYSTIC study. *Angiogenesis*. 2021;24(1):145-57.
- 596 26. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brügggen MC, et al. Immune  
597 response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.  
598 *Allergy*. 2020;75(7):1564-81.
- 599 27. Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, Gkaliagkousi E. Endothelial  
600 Dysfunction in COVID-19: Lessons Learned from Coronaviruses. *Current hypertension*  
601 *reports*. 2020;22(9):1-12.
- 602 28. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and  
603 cardiac pathology in African American patients with COVID-19: an autopsy series from New  
604 Orleans. *The Lancet Respiratory Medicine*. 2020;8(7):681-6.

- 605 29. Arachchillage DJ, Stacey A, Akor F, Scotz M, Laffan M. Thrombolysis restores perfusion in  
606 COVID-19 hypoxia. *British journal of haematology*. 2020;190(5):e270-e4.
- 607 30. Doglioni C, Ravaglia C, Chilosi M, Rossi G, Dubini A, Pedica F, et al. Covid-19 interstitial  
608 pneumonia: histological and immunohistochemical features on cryobiopsies. *Respiration*.  
609 2021;100(5):369-79.
- 610 31. Dumoulin DW, Gietema HA, Paats MS, Hendriks LE, Cornelissen R. Differentiation of  
611 COVID-19 pneumonitis and ICI induced pneumonitis. *Frontiers in oncology*. 2020;10.
- 612 32. Ekanem E, Podder S, Donthi N, Bakhshi H, Stodghill J, Khandhar S, et al. Spontaneous  
613 pneumothorax: An emerging complication of COVID-19 pneumonia. *Heart & Lung*.  
614 2021;50(3):437-40.
- 615 33. Elhakim TS, Abdul HS, Romero CP, Rodriguez-Fuentes Y. Spontaneous  
616 pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia:  
617 a rare case and literature review. *BMJ Case Reports CP*. 2020;13(12):e239489.
- 618 34. Zantah M, Castillo ED, Townsend R, Dikengil F, Criner GJ. Pneumothorax in COVID-19  
619 disease-incidence and clinical characteristics. *Respiratory Research*. 2020;21(1):1-9.
- 620 35. Mastellos DC, da Silva BGP, Fonseca BA, Fonseca NP, Auxiliadora-Martins M, Mastaglio S,  
621 et al. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal  
622 differential biological efficacy. *Clinical Immunology*. 2020;220:108598.
- 623 36. Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. *Nature*  
624 *Reviews Immunology*. 2020;20(7):389-91.
- 625 37. Sun X, Wang T, Cai D, Hu Z, Liao H, Zhi L, et al. Cytokine storm intervention in the early  
626 stages of COVID-19 pneumonia. *Cytokine & growth factor reviews*. 2020;53:38-42.
- 627 38. Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, et al. Convalescent plasma  
628 therapy in patients with COVID-19. *Transfusion and Apheresis Science*. 2021;60(1):102955.
- 629 39. Gómez-Pastora J, Weigand M, Kim J, Wu X, Strayer J, Palmer AF, et al. Hyperferritinemia in  
630 critically ill COVID-19 patients—Is ferritin the product of inflammation or a pathogenic  
631 mediator? *Clinica Chimica Acta; International Journal of Clinical Chemistry*. 2020.

- 632 40. Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Saadat SH, et al. Safety  
633 and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. *International*  
634 *immunopharmacology*. 2021;95:107522.
- 635 41. Raju R, Prajith V, Biatrix PS. Therapeutic role of corticosteroids in COVID-19: a systematic  
636 review of registered clinical trials. *Future Journal of Pharmaceutical Sciences*. 2021;7(1):1-18.
- 637 42. Group RC. Dexamethasone in hospitalized patients with Covid-19. *New England Journal of*  
638 *Medicine*. 2021;384(8):693-704.
- 639 43. Pinna SM, Scabini S, Corcione S, Lupia T, De Rosa FG. COVID-19 pneumonia: do not leave  
640 the corticosteroids behind! *Future Microbiology*. 2021;16(5):317-22.
- 641 44. Erçen Diken , Yıldırım F, Yıldız Guşlhan P, Özkaya Ş, Şimşek M, Yuşcel C et al.  
642 Corticosteroid use in COVID-19 pneumonia. *Tuberk Toraks* 2021;69(2):217-226.
- 643 45. Chrousos GP, Meduri GU. Critical COVID-19 disease, homeostasis, and the “surprise” of  
644 effective glucocorticoid therapy. *Clinical Immunology (Orlando, Fla.)*. 2020;219:108550.
- 645 46. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of  
646 methylprednisolone therapy in severe patients with COVID-19 pneumonia. *Signal*  
647 *transduction and targeted therapy*. 2020;5(1):1-3.
- 648 47. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients  
649 hospitalized with Covid-19 pneumonia. *New England Journal of Medicine*. 2021;384(1):20-  
650 30.
- 651 48. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low  
652 dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *European*  
653 *journal of internal medicine*. 2020;76:31-5.
- 654 49. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association  
655 between early treatment with tocilizumab and mortality among critically ill patients with  
656 COVID-19. *JAMA internal medicine*. 2021;181(1):41-51.
- 657 50. Bickdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and  
658 thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy,  
659 and follow-up: JACC state-of-the-art review. *Journal of the American college of cardiology*.  
660 2020;75(23):2950-73.

661 51. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20  
662 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation  
663 Protocol: prospective observational cohort study. *bmj*. 2020;369.

664

665

666

667

668 **Table 1. The Characteristics of Patients with COVID-19**

<i>Characteristics</i>	<i>n(%)</i>
<i>Age (mean ±SD)</i>	59.2 ±17.3
<b><i>Gender</i></b>	
<i>Male/Female</i>	5507/5683
<b><i>Symptoms</i></b>	
<i>Asymptomatic</i>	2460(21.9%)
<i>Cough</i>	6870(54.5%)
<i>Pain</i>	5370(47.9%)
<i>Dyspnea</i>	4140(36.9%)
<i>Fever</i>	3540(31.6%)
<b><i>Pneumonitis</i></b>	5061 (45.2%)
<b><i>Patient groups</i></b>	
<i>Group A</i>	9294 (83,05%)
<i>Group B</i>	1376(12.29%)
<i>Group C</i>	520(4.64%)
<b><i>Hospitalized patients</i></b>	1896(16.9%)
<i>in first 10 days</i>	1220(64.3%)
<i>after 10 days</i>	676 (35.7%)
<b><i>Respiratory Failure</i></b>	520 (27.4%)

*NIMV + IMV\*\** 146(7.7%)

*Mortality* 43(2.2%)

---

669 \**NIMV*:Non-Invasive Mechanical Ventilation

670 \*\**IMV* :Invasive Mechanical Ventilation

671

672

673

674

675

676

677 **Figure 1** consists of 7 cases with variable stages of COVID-19 and examples of early and severe  
678 endotheliitis in brain, pulmonary and skin tissues. Histopathological and radiological findings of  
679 pneumonitis changed depending on the phase of the disease (early, progressive, severe and dissipative,  
680 respectively), which leads to a divergence in treatment groups.

681

682 *Examples of patients who were convenient for **Group A** treatment are depicted in sections I-II.*

683

684 **Figure 1-I. Case 1.** HRCT images showed patchy, subpleural and peripheral perivascular ground-  
685 glass opacities, corresponding the early phase of pneumonitis. She received Group A treatment. GGOs  
686 in transaxial images were located in the subpleural area, where the microvascular *endoteheliitis* and  
687 endothelial destructions mostly likely occur, due to the interaction with toxic plasma in the capillaries  
688 of pulmonary interstitial space.

689

690 **Figure 1-II. Case 2.** HRCT images showed characteristics of an early phase COVID-19 pneumonitis  
691 (end-capillary microangiopathy, explained in Fig.1-I) and perivascular consolidation. It appeared as  
692 the continuation of crazy-paving pattern, which was demonstrated by the thickening in inter-lobular  
693 and intra-lobular septa. Lung involvement was limited and monofocal. Hence, the patient received  
694 Group A treatment.

695

696 *An example of a patient who was convenient for **Group B** treatment is depicted in section III.*

697

698 **Figure 1-III. Case 3.**Transaxial HRCT image in the first day of positivity shows bilateral and patchy  
699 nodular GGOs as expected in early phase (**IIIa**). At the 5th day of positivity, affected pulmonary  
700 areas were advanced into scattered consolidations (**IIIb**). This appearance was noted as the  
701 progressive phase of pneumonitis and was considered as representation of clinical deterioration  
702 clinically (i.e. dyspnea, respiratory failure). On the 15<sup>th</sup> day of positivity, fibroreticular consolidations

703 were conspicuous (**IIIc**). The dissipative phase was the healing process, characterized by the  
704 resolution in lung parenchyma and residual GGO, observed after 35 days of positivity (**IIIId**).  
705 Parenchymal bands, originated from previous fibroreticular proliferation, were also visible (**IIIId**).

706

707 *If the patients have a tendency of severe phase and/or unresponsiveness to Group B therapy, **Group C***  
708 *treatment was used. Representative cases of this group are shown in sections **IV-V-VI-VII**. This group*  
709 *of patients also undergo early and progressive phases of COVID-19 but they also showed further*  
710 *deterioration of lung involvement and endothelial damage, therefore, they received the last group of*  
711 *treatment. For the description of early and progressive phases, sections **I, II** and can be referred.*

712

713 **Figure 1-IV. Case 4.** Coronal, sagittal and axial planes of HRCT images initially showed small GGO  
714 with a local subpleural sparing, particularly around the microvascular area on the first day of positivity  
715 (**IVa**). In the 5<sup>th</sup> day of treatment, increased GGOs were visible in the progressive phase (**IVb**). After  
716 18 days of positivity, pneumomediastinum, Diffuse Alveolar Damage (DAD) and ARDS were seen in  
717 the severe phase (**IVc**). Lastly, the dissipative phase was seen, after 30 days of positivity, with residual  
718 fibrotic parenchyma (**IVd**).

719

720 **Figure 1-V. Case 5.** The first HRCT image, on the 2<sup>nd</sup> day of positivity, showed COVID-19-related  
721 bilateral and multifocal nodular GGOs (**Va**). After 10 days of positivity, DAD developed along with  
722 ARDS and pneumomediastinum characterized with the severe phase (**Vb**). She recovered and  
723 discharged after 30 days of positivity with the dissipative phase (**Vc**). The regression in pulmonary  
724 lesions was visible on the HRCT image two months after diagnosis (**Vd**).

725

726 **Figure 1-VI. Case 6.** HRCT image showed moderate pneumonia in the early phase (**VIa**). After 12  
727 days of positivity, the severe phase develops with DAD and ARDS (**VIb**). In the 25<sup>th</sup> day of  
728 positivity, recovery was observed in the dissipative phase (**VIc**). The extent of improvement in  
729 pulmonary lesions can be noticed in **VIId**, which was 40 days after the diagnosis.

730

731 **Figure 1-VII. Case 7.** First HRCT showed ARDS pattern with dense consolidations (**VIIa**).  
732 Pneumothorax developed after two weeks from diagnosis (**VIIb**). In addition to the respiratory failure,  
733 hemorrhagical intracranial areas were seen in the T2-weighted MRI. (**VIIc**). He was lost at the 20<sup>th</sup>  
734 day of positivity.

735

736 *Representative histopathological and radiological images of endotheliitis is seen in section **VIII, IX,***  
737 ***X, XI.***

738

739 **Figure 1-VIII** Haematoxylin&Eosin-stained sections from representative areas of lung parenchyma  
740 were seen with the mixt-type inflammatory-cell infiltration of lung tissue and exudative capillaritis  
741 with thickened microvascular walls. Interstitial and intra-alveolar proliferation of fibroblasts are noted.

742

743 **Figure 1-IX. Diffusion MRI** of head image of COVID-19 positive patient showing characteristic  
744 COVID-19 related *endotheliitis* causing characteristic lesions and intracranial hemorrhage.

745


746 **Figure 1-X** Early *endotheliitis*.

747 **Figure 1-XI** Late *endotheliitis*.

748 **Figure 1-XII** Papulovesicular eruptions as the skin manifestations of COVID-19 related *endotheliitis*.

749

750



751

